Dose–response, therapeutic time-window and tPA-combinatorial efficacy of compound 21: A randomized, blinded preclinical trial in a rat model of thromboembolic stroke

Tauheed Ishrat, Abdelrahman Y. Fouda, Bindu Pillai, Wael Eldahshan, Heba Ahmed, Jennifer L Waller, Adviye Ergul, Susan C. Fagan

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The aim of this translational, randomized, controlled, blinded preclinical trial was to determine the effect of compound 21 (C21) in embolic stroke. Rats were subjected to embolic-middle cerebral artery occlusion (eMCAO). They received C21 (0.01, 0.03 and 0.06 mg/kg/d) or saline (orally) for five days, with the first-dose given IV at 3 h post-eMCAO. For the time-window study, the optimal-dose of C21 was initiated at 3, 6 or 24 h post-eMCAO and continued for five days. For the combinatorial study, animals received IV-tissue plasminogen activator (tPA) at either 2 or 4 h, with IV-C21 (0.01 mg/kg) or saline at 3 h post-eMCAO and daily thereafter for five days. After performing the behavior tests, brains were collected for analyses. The dose–response study showed significant motor improvements with the lowest-dose (0.01 mg/kg) of C21. In the time-window study, this same dose resulted in improvements when given 6 h and 24 h post-eMCAO. Moreover, C21-treated animals performed better on the novel object recognition test. Neither the single treatment with C21 or tPA (4 h) nor the combination therapy was effective in reducing the hemorrhage or infarct size, although C21 alone lowered sensorimotor deficit scores post-eMCAO. Future studies should focus on the long-term cognitive benefits of C21, rather than acute neuroprotection.

Original languageEnglish (US)
Pages (from-to)1635-1647
Number of pages13
JournalJournal of Cerebral Blood Flow and Metabolism
Volume39
Issue number8
DOIs
StatePublished - Aug 1 2019

Fingerprint

Middle Cerebral Artery Infarction
Tissue Plasminogen Activator
Stroke
Therapeutics
Hemorrhage
Brain

Keywords

  • Compound C21
  • embolic middle cerebral artery occlusion
  • functional outcome
  • ischemic stroke
  • tissue plasminogen activator

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine

Cite this

Dose–response, therapeutic time-window and tPA-combinatorial efficacy of compound 21 : A randomized, blinded preclinical trial in a rat model of thromboembolic stroke. / Ishrat, Tauheed; Fouda, Abdelrahman Y.; Pillai, Bindu; Eldahshan, Wael; Ahmed, Heba; Waller, Jennifer L; Ergul, Adviye; Fagan, Susan C.

In: Journal of Cerebral Blood Flow and Metabolism, Vol. 39, No. 8, 01.08.2019, p. 1635-1647.

Research output: Contribution to journalArticle

Ishrat, Tauheed ; Fouda, Abdelrahman Y. ; Pillai, Bindu ; Eldahshan, Wael ; Ahmed, Heba ; Waller, Jennifer L ; Ergul, Adviye ; Fagan, Susan C. / Dose–response, therapeutic time-window and tPA-combinatorial efficacy of compound 21 : A randomized, blinded preclinical trial in a rat model of thromboembolic stroke. In: Journal of Cerebral Blood Flow and Metabolism. 2019 ; Vol. 39, No. 8. pp. 1635-1647.
@article{4f60b02b264c424091bc338d10383fa7,
title = "Dose–response, therapeutic time-window and tPA-combinatorial efficacy of compound 21: A randomized, blinded preclinical trial in a rat model of thromboembolic stroke",
abstract = "The aim of this translational, randomized, controlled, blinded preclinical trial was to determine the effect of compound 21 (C21) in embolic stroke. Rats were subjected to embolic-middle cerebral artery occlusion (eMCAO). They received C21 (0.01, 0.03 and 0.06 mg/kg/d) or saline (orally) for five days, with the first-dose given IV at 3 h post-eMCAO. For the time-window study, the optimal-dose of C21 was initiated at 3, 6 or 24 h post-eMCAO and continued for five days. For the combinatorial study, animals received IV-tissue plasminogen activator (tPA) at either 2 or 4 h, with IV-C21 (0.01 mg/kg) or saline at 3 h post-eMCAO and daily thereafter for five days. After performing the behavior tests, brains were collected for analyses. The dose–response study showed significant motor improvements with the lowest-dose (0.01 mg/kg) of C21. In the time-window study, this same dose resulted in improvements when given 6 h and 24 h post-eMCAO. Moreover, C21-treated animals performed better on the novel object recognition test. Neither the single treatment with C21 or tPA (4 h) nor the combination therapy was effective in reducing the hemorrhage or infarct size, although C21 alone lowered sensorimotor deficit scores post-eMCAO. Future studies should focus on the long-term cognitive benefits of C21, rather than acute neuroprotection.",
keywords = "Compound C21, embolic middle cerebral artery occlusion, functional outcome, ischemic stroke, tissue plasminogen activator",
author = "Tauheed Ishrat and Fouda, {Abdelrahman Y.} and Bindu Pillai and Wael Eldahshan and Heba Ahmed and Waller, {Jennifer L} and Adviye Ergul and Fagan, {Susan C.}",
year = "2019",
month = "8",
day = "1",
doi = "10.1177/0271678X18764773",
language = "English (US)",
volume = "39",
pages = "1635--1647",
journal = "Journal of Cerebral Blood Flow and Metabolism",
issn = "0271-678X",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Dose–response, therapeutic time-window and tPA-combinatorial efficacy of compound 21

T2 - A randomized, blinded preclinical trial in a rat model of thromboembolic stroke

AU - Ishrat, Tauheed

AU - Fouda, Abdelrahman Y.

AU - Pillai, Bindu

AU - Eldahshan, Wael

AU - Ahmed, Heba

AU - Waller, Jennifer L

AU - Ergul, Adviye

AU - Fagan, Susan C.

PY - 2019/8/1

Y1 - 2019/8/1

N2 - The aim of this translational, randomized, controlled, blinded preclinical trial was to determine the effect of compound 21 (C21) in embolic stroke. Rats were subjected to embolic-middle cerebral artery occlusion (eMCAO). They received C21 (0.01, 0.03 and 0.06 mg/kg/d) or saline (orally) for five days, with the first-dose given IV at 3 h post-eMCAO. For the time-window study, the optimal-dose of C21 was initiated at 3, 6 or 24 h post-eMCAO and continued for five days. For the combinatorial study, animals received IV-tissue plasminogen activator (tPA) at either 2 or 4 h, with IV-C21 (0.01 mg/kg) or saline at 3 h post-eMCAO and daily thereafter for five days. After performing the behavior tests, brains were collected for analyses. The dose–response study showed significant motor improvements with the lowest-dose (0.01 mg/kg) of C21. In the time-window study, this same dose resulted in improvements when given 6 h and 24 h post-eMCAO. Moreover, C21-treated animals performed better on the novel object recognition test. Neither the single treatment with C21 or tPA (4 h) nor the combination therapy was effective in reducing the hemorrhage or infarct size, although C21 alone lowered sensorimotor deficit scores post-eMCAO. Future studies should focus on the long-term cognitive benefits of C21, rather than acute neuroprotection.

AB - The aim of this translational, randomized, controlled, blinded preclinical trial was to determine the effect of compound 21 (C21) in embolic stroke. Rats were subjected to embolic-middle cerebral artery occlusion (eMCAO). They received C21 (0.01, 0.03 and 0.06 mg/kg/d) or saline (orally) for five days, with the first-dose given IV at 3 h post-eMCAO. For the time-window study, the optimal-dose of C21 was initiated at 3, 6 or 24 h post-eMCAO and continued for five days. For the combinatorial study, animals received IV-tissue plasminogen activator (tPA) at either 2 or 4 h, with IV-C21 (0.01 mg/kg) or saline at 3 h post-eMCAO and daily thereafter for five days. After performing the behavior tests, brains were collected for analyses. The dose–response study showed significant motor improvements with the lowest-dose (0.01 mg/kg) of C21. In the time-window study, this same dose resulted in improvements when given 6 h and 24 h post-eMCAO. Moreover, C21-treated animals performed better on the novel object recognition test. Neither the single treatment with C21 or tPA (4 h) nor the combination therapy was effective in reducing the hemorrhage or infarct size, although C21 alone lowered sensorimotor deficit scores post-eMCAO. Future studies should focus on the long-term cognitive benefits of C21, rather than acute neuroprotection.

KW - Compound C21

KW - embolic middle cerebral artery occlusion

KW - functional outcome

KW - ischemic stroke

KW - tissue plasminogen activator

UR - http://www.scopus.com/inward/record.url?scp=85045071802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045071802&partnerID=8YFLogxK

U2 - 10.1177/0271678X18764773

DO - 10.1177/0271678X18764773

M3 - Article

AN - SCOPUS:85045071802

VL - 39

SP - 1635

EP - 1647

JO - Journal of Cerebral Blood Flow and Metabolism

JF - Journal of Cerebral Blood Flow and Metabolism

SN - 0271-678X

IS - 8

ER -